Summary
The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) seeks to characterize the longitudinal course of HIV treatment, progression, and outcomes, assess chronic diseases and co-infections, and expand epidemiologic, biostatistical, and data science methodologies for the next funding cycle.
What they want
The NA-ACCORD, representing Region 1 of the IeDEA initiative, will continue to leverage data from over 190,000 people with HIV across more than 20 clinical and epidemiologic HIV cohorts in the US. The work involves three main aims: 1) Characterizing the longitudinal course of HIV treatment, progression, and outcomes, focusing on increasing heterogeneity in HIV care as challenges evolve. 2) Assessing and characterizing the clinical course of HIV infection, with a focus on major chronic diseases, co-infections, multimorbidity, and life expectancy. 3) Expanding and extending state-of-the-art epidemiologic, biostatistical, and data science methodologic approaches. The collaboration aims to provide in-depth understanding of HIV's longitudinal course, understand differences in treatment and outcomes, collaborate with other IeDEA regions, and contribute to methodology development for large-scale longitudinal studies.
Deliverables
- Characterization of the longitudinal course of HIV treatment, progression, and outcome
- Assessment and characterization of the clinical course of HIV infection, chronic diseases, co-infections, multimorbidity, and life expectancy
- Expanded and extended epidemiologic, biostatistical, and data science methodologic approaches
Technical requirements
- State-of-the-art epidemiologic, biostatistical, and data science methodologic approaches
Key personnel
- Clinical researchers
- Epidemiologists
- Data scientists
- Biostatisticians
